Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Development of a Predictive Model for Sexually Transmitted Infections in Individuals Using Pre-Exposure Prophylaxis for HIV in Spain

NCT06860945 · tracked via the Priya Life Science Spain tracker
Sponsor
Hospital Universitario de Valme
Phase
Observational
Started
2025-01-01
Last updated
2025-03-06

Condition(s) studied

Sexually Transmitted Infections (STIs)HIVPrEP

Investigational drug(s) / intervention(s)

No Intervention: Observational Cohort

No Intervention: Observational Cohort: No Intervention: Observational Cohort

Study summary

Objective: To develop and validate a predictive model for acquiring sexually transmitted infections (STIs) in individuals using HIV pre-exposure prophylaxis (PrEP) within the national program providing this strategy.

Methods: Ambispective cohort study, multicentric (23 Spanish hospitals). All PrEP users, with follow-up within the program, will be included. Entry into the program will be considered as the baseline visit. From there, patients are followed quarterly, following the national protocols for monitoring PrEP users in Spain. At each visit, diagnosis of different STIs (serum, pharyngeal swab, urethral or urine sample, rectal swab, endocervical/vaginal swab, ulcer) is performed. Primary outcome variable: development of an STI (Yes/No). The following STIs will be considered: syphilis, Neisseria gonorrhoeae (NG) infection, Chlamydia trachomatis (CT) infection, lymphogranuloma venereum (LGV), Mycoplasma genitalium (MG) infection, genital herpes, hepatitis A, hepatitis B, hepatitis C, HIV infection, and MPOX. Secondary outcome variable: number of diagnosed STIs. In order to determine factors associated with acquiring an STI, multivariate analyses will be conducted using logistic regression. The best models will be analyzed in the validation population. To compare the models, we will follow the Bayesian approach suggested by Benavoli et al.

Eligibility

Sex
ALL
Min age
16 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * All individuals with documented initiation of oral PrEP (daily or event-driven regimens), who have collected the medication at least once and have taken at least one pill, will be included in the study. The approved criteria for the use of oral PrEP in Spain, as recommended by the Spanish Gesida guidelines (GeSIDA. Recomendaciones sobre la Profilaxis Pre-Exposición para la Prevención de la Infección por VIH en España. Marzo 2023. Available at http://.gesida-seimc.org/category/guias-clinicas/otras-guias-vigentes/), are as follows: * People without HIV infection at the time of cohort inclusion * Age ≥ 16 yr who meet the following criteria: * MSM and transgender women with at least two of the following criteria during the last year: \> 10 sexual partners; Condomless anal sex; Chemsex; PEP; ≥ 1 STI * Sex worker women who report non-habitual use of condoms. * Cisgender males/females, who report condomless and present at least two of the same criteria as MSM and transgender. * PWID with unsafe injection practices Exclusion Criteria: none \-

Primary outcome measure(s)

  • STI predictive model — through study completion, an average of 5 years
    Predictive model for the acquisition of sexually transmitted infections in individuals using PrEP within the national provision program for this strategy

Trial sites (26)

FacilityCityRegionStatus
Hospital Universitario de Torrecárdenas Almería Spain Recruiting
Hospital Universitario Puerto Real Cadiz Spain Recruiting
Hospital Universitario Santa Lucía Cartagena Spain Recruiting
hospital Universitario reina Sofía Córdoba Spain Recruiting
Hospital Virgen de la Luz Cuenca Spain Recruiting
Hospital Universitario de Elche Elche Spain Recruiting
Hospital Clínico Universitario San Cecilio Granada Spain Recruiting
Hospital Universitario Virgen de las Nieves Granada Spain Recruiting
Hospital Universitario Juan Ramón Jiménez Huelva Spain Recruiting
Complejo Hospitalario de Jaén Jaén Spain Recruiting
Hospital de Jerez de la Frontera Jerez de la Frontera Spain Recruiting
Hospital Universitario de Bellvitge L'Hospitalet de Llobregat Spain Recruiting
Hospital Universitario Dr. Negrín Las Palmas de Gran Canaria Spain Recruiting
Centro Sanitario Sandoval Madrid Spain Recruiting
Hospital Fundación Jiménez Díaz Madrid Spain Recruiting
Hospital Universitario Infanta Leonor Madrid Spain Recruiting
Hospital Universitario La Princesa Madrid Spain Recruiting
Hospital Regional Universitario de Málaga Málaga Spain Recruiting
Hospital Universitario Virgen de la Victoria Málaga Spain Recruiting
Hospital Universitario Virgen de la Arrixaca Murcia Spain Recruiting
Hospital Universitario Marqués de Valdecilla Santander Spain Recruiting
Hospital Universitario Virgen de la Macarena Seville Spain Recruiting
Hospital Universitario Virgen de Valme Seville Spain Recruiting
Hospital Universitario Virgen del Rocío Seville Spain Recruiting
Hospital Universitario de Valladolid Valladolid Spain Recruiting
Hospital Universitario Álvaro Cunqueiro Vigo Spain Recruiting

More Hospital Universitario de Valme trials in Spain

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06860945 on ClinicalTrials.gov ↗ ← All trials in Spain